Total Payments
$1.2M
2024 Payments
$249,827
Companies
55
Transactions
2,775
Medicare Patients
1,908
Medicare Billing
$335,322
Payment Breakdown by Category
Other$856,623 (72.0%)
Travel$134,942 (11.3%)
Consulting$118,240 (9.9%)
Food & Beverage$54,296 (4.6%)
Research$24,899 (2.1%)
Education$279.26 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $769,678 | 312 | 64.7% |
| Travel and Lodging | $134,942 | 476 | 11.3% |
| Consulting Fee | $118,240 | 35 | 9.9% |
| Grant | $86,445 | 4 | 7.3% |
| Food and Beverage | $54,296 | 1,918 | 4.6% |
| Unspecified | $24,899 | 19 | 2.1% |
| Honoraria | $500.00 | 1 | 0.0% |
| Education | $279.26 | 10 | 0.0% |
Payments by Type
General
$1.2M
2,756 transactions
Research
$24,899
13 transactions
Ownership
$0
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $246,675 | 199 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $233,724 | 427 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $203,579 | 480 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $104,700 | 308 | $0 (2022) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $85,793 | 70 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $85,058 | 214 | $0 (2024) |
| ITI, Inc. | $75,862 | 134 | $0 (2023) |
| Alkermes, Inc. | $25,364 | 104 | $0 (2024) |
| Axsome Therapeutics, Inc. | $23,848 | 38 | $0 (2024) |
| ABBVIE INC. | $16,974 | 94 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $249,827 | 407 | Otsuka America Pharmaceutical, Inc. ($91,229) |
| 2023 | $135,694 | 395 | Janssen Pharmaceuticals, Inc ($46,789) |
| 2022 | $122,001 | 357 | Janssen Pharmaceuticals, Inc ($58,915) |
| 2021 | $65,176 | 313 | ITI, Inc. ($18,529) |
| 2020 | $54,994 | 211 | ACADIA Pharmaceuticals Inc ($20,636) |
| 2019 | $219,258 | 433 | ACADIA Pharmaceuticals Inc ($69,595) |
| 2018 | $174,282 | 309 | ACADIA Pharmaceuticals Inc ($104,017) |
| 2017 | $168,046 | 350 | ACADIA Pharmaceuticals Inc ($47,809) |
All Payment Transactions
2,775 individual payment records from CMS Open Payments — Page 1 of 111
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.91 | General |
| Category: NEUROSCIENCE | ||||||
| 12/19/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,400.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/19/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $1,406.75 | General |
| Category: PSYCHIATRY | ||||||
| 12/19/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $130.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/19/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Insomnia | ||||||
| 12/18/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $22.64 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.63 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $4.25 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/13/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $27.19 | General |
| Category: Neuroscience | ||||||
| 12/13/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $25.73 | General |
| Category: Neuroscience | ||||||
| 12/12/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Neuroscience | ||||||
| 12/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.14 | General |
| Category: NEUROSCIENCE | ||||||
| 12/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.69 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,400.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $590.20 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | Cash or cash equivalent | $87.62 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,780.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $434.94 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Food and Beverage | In-kind items and services | $28.75 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: PSYCHIATRY | ||||||
| 12/02/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Consulting Fee | Cash or cash equivalent | $2,940.00 | General |
| Category: Neuroscience | ||||||
| 12/01/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Consulting Fee | Cash or cash equivalent | $2,940.00 | General |
| Category: Neuroscience | ||||||
| 11/26/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Neuropsychiatry | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY | Eli Lilly and Company | $13,630 | 4 |
| ACA 16-cAC-0001 | ACADIA Pharmaceuticals Inc | $10,500 | 6 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $450.00 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $300.00 | 1 |
| A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $19.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 472 | 975 | $416,282 | $215,010 |
| 2022 | 7 | 404 | 673 | $65,771 | $34,825 |
| 2021 | 7 | 465 | 873 | $79,074 | $44,015 |
| 2020 | 8 | 567 | 855 | $86,104 | $41,472 |
Total Patients
1,908
Total Services
3,376
Medicare Billing
$335,322
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G2083 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, | Office | 2023 | 13 | 203 | $345,100 | $180,269 | 52.2% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 122 | 122 | $30,500 | $16,035 | 52.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 69 | 105 | $15,750 | $7,961 | 50.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 26 | 27 | $5,940 | $2,599 | 43.8% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 34 | 46 | $4,140 | $2,240 | 54.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 33 | $3,300 | $1,409 | 42.7% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2023 | 13 | 24 | $3,000 | $1,369 | 45.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 14 | 18 | $2,250 | $878.94 | 39.1% |
| 90785 | Psychiatric services complicated by communication factor | Office | 2023 | 69 | 76 | $1,748 | $801.09 | 45.8% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 38 | 222 | $1,784 | $732.75 | 41.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 16 | 64 | $2,560 | $696.96 | 27.2% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 32 | 35 | $210.00 | $17.00 | 8.1% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 105 | 105 | $26,250 | $13,735 | 52.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 101 | 154 | $23,100 | $12,690 | 54.9% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 49 | 68 | $6,120 | $3,194 | 52.2% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2022 | 21 | 41 | $5,125 | $2,744 | 53.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 18 | $1,800 | $928.59 | 51.6% |
| 90785 | Psychiatric services complicated by communication factor | Office | 2022 | 63 | 72 | $1,656 | $802.14 | 48.4% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2022 | 48 | 215 | $1,720 | $731.20 | 42.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 122 | 198 | $29,700 | $17,541 | 59.1% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 118 | 118 | $29,500 | $15,991 | 54.2% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 64 | 89 | $8,010 | $4,675 | 58.4% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2021 | 20 | 44 | $5,500 | $2,801 | 50.9% |
| 90785 | Interactive complexity | Office | 2021 | 87 | 102 | $2,346 | $1,169 | 49.8% |
| 96127 | Brief emotional or behavioral assessment | Office | 2021 | 39 | 306 | $2,448 | $1,115 | 45.6% |
About Dr. Horacio Capote, M.D
Dr. Horacio Capote, M.D is a Psychiatry healthcare provider based in Amherst, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053475939.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Horacio Capote, M.D has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $249,827 received in 2024. These payments were reported across 2,775 transactions from 55 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($769,678).
As a Medicare-enrolled provider, Capote has provided services to 1,908 Medicare beneficiaries, totaling 3,376 services with total Medicare billing of $335,322. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Amherst, NY
- Active Since 12/21/2006
- Last Updated 02/09/2017
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1053475939
Products in Payments
- NUPLAZID (Drug) $246,675
- REXULTI (Drug) $212,013
- SPRAVATO (Drug) $204,901
- CAPLYTA (Drug) $161,655
- LATUDA (Drug) $104,443
- AUSTEDO (Drug) $67,480
- Auvelity (Drug) $23,744
- VRAYLAR (Drug) $23,316
- ABILIFY MAINTENA (Drug) $22,931
- Aristada 441 mg (Drug) $19,545
- Austedo XR (Drug) $16,381
- BELSOMRA (Drug) $12,483
- Trintellix (Drug) $10,359
- Lucemyra/Lofexidine (Drug) $10,267
- AMYVID (Drug) $6,900
- Vivitrol 380 mg (Drug) $4,251
- NUEDEXTA (Drug) $3,477
- SUNOSI (Drug) $1,938
- QUVIVIQ (Drug) $1,568
- ARISTADA (Drug) $1,410
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Amherst
Dr. Adam Ashton, M.d, M.D
Psychiatry — Payments: $1.7M
Psychiatry $1.7M
Maria Nickolova, M.d, M.D
Psychiatry — Payments: $26,524
Psychiatry $26,524
Rebecca Phillips, Md, MD
Psychiatry — Payments: $17,128
Psychiatry $17,128
Andrew Reichert, M.d, M.D
Psychiatry — Payments: $14,912
Psychiatry $14,912
Maria Cartagena, M.d, M.D
Psychiatry — Payments: $10,432
Psychiatry $10,432
Syed Jaffri, M.d.,M.r.c.,Psych, M.D.,M.R.C.,PSYCH
Psychiatry — Payments: $10,142
Psychiatry $10,142